SCHEMBL7515798

SCHEMBL7515798

Cc1cc(C)c(S(=O)(=O)C(N)CCCNC(c2ccccc2)(c2ccccc2)c2ccccc2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
NR3C1 P04150 5/20 0.39
KIF11 P52732 1/20 0.39
PGR P06401 4/20 0.37
NR3C2 P08235 4/20 0.37
FFAR4 Q5NUL3 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
KCNN4 O15554 1/20 0.35
LMNA P02545 2/20 0.34
TP53 P04637 1/20 0.34
FABP4 P15090 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.34
DUT P33316 1/20 0.34
EPHX2 P34913 1/20 0.34
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7515730 0.93 L3MBTL1 (0.41) L3MBTL1NR3C1KIF11PGRNR3C2
SCHEMBL4746886 0.76 NR3C1 (0.36) L3MBTL1NR3C1PGRNR3C2MAPT
SCHEMBL4821971 0.74 F2 (0.43) L3MBTL1NR3C1PGRNR3C2LMNA
SCHEMBL7525267 0.71 KEAP1 (0.39) L3MBTL1KIF11FFAR4MAPTKCNN4
SCHEMBL7523376 0.71 KEAP1 (0.39) L3MBTL1KIF11FFAR4MAPTKCNN4
SCHEMBL7513698 0.70 KEAP1 (0.38) L3MBTL1KIF11FFAR4MAPTKCNN4
SCHEMBL14935909 0.70 KIF11 (0.61) KIF11
SCHEMBL1905808 0.70 KIF11 (0.61) KIF11
SCHEMBL22361680 0.70 KIF11 (0.61) KIF11
SCHEMBL30148489 0.67 KIF11 (0.60) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020045780-A1 Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment BERGERON RAYMOND J (US) 2002-04-18 US disclosed
US-6235794-B1 ANTICANCER AGENT UNIVERSITY OF FLORIDA 2001-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045780-A1 Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment SRM, SLC7A1, CATSPER1 L3MBTL1 3921/4885NR3C1 1332/4885KIF11 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.